First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

A pilot trial tested the nasal administration of the drug Foralumab, an anti-CD3 monoclonal antibody. Investigators found evidence that the drug dampened the inflammatory T cell response and decreased lung inflammation in patients with COVID-19. Further analysis showed the same gene expression modulation in patients with multiple sclerosis, who experienced decreased brain inflammation, suggesting that Foralumab could be used to treat other diseases.

from Top Health News -- ScienceDaily https://ift.tt/qumd1D2